Arbutus Announces Corporate Update and First Quarter 2018 Financial Results
03 mai 2018 16h00 HE
|
Arbutus Biopharma Corporation
Two Novel HBV Candidates Planned to Enter Clinical Development in 2018GalNAc Conjugated RNAi Agent Nominated to Enter IND-Enabling Studies Strategic Partnership with Roivant to Launch Genevant, an RNA...
Arbutus Announces Conference Call to Provide a Corporate Update and First Quarter 2018 Financial Results
30 avr. 2018 09h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and WARMINSTER, Pa., April 30, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...
Arbutus Presents Complementary Results From Preclinical Combination Studies of HBV Therapeutic Candidates at EASL 2018
12 avr. 2018 12h00 HE
|
Arbutus Biopharma Corporation
Capsid inhibitor with HBV RNA Destabilizer Demonstrate Complementary Efficacy ResultsSubcutaneous RNAi Agent Demonstrates Durable HBsAg Reduction Following a Single Dose VANCOUVER, British Columbia...
Arbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA Therapeutics for Genetic Diseases
11 avr. 2018 17h24 HE
|
Arbutus Biopharma Corporation
Genevant aims to advance 5-10 product candidates into the clinic by 2020 across RNAi, mRNA, and gene editing modalities using Arbutus’ LNP and ligand conjugate platformsGenevant will be led by...
Arbutus to Present HBV Data at 2018 EASL Liver Meeting
28 mars 2018 17h54 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and WARMINSTER, Pa., March 28, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...
Arbutus Announces Corporate Update and Year-End 2017 Financial Results
14 mars 2018 16h00 HE
|
Arbutus Biopharma Corporation
ARB-1467 Phase II Combination Study Beginning in 1Q18Two New Drug Candidates Planned to Enter Clinical Development in 2H18Over $200M in Cash Available to Fund Development of HBV AssetsCompany to Host...
Arbutus Announces Conference Call to Provide a Corporate Update and Fourth Quarter 2017 Year-End Financial Results
12 mars 2018 09h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and WARMINSTER, Pa., March 12, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...
Arbutus Settles Litigation, Terminating Acuitas’ Rights to LNP Technology
22 févr. 2018 16h35 HE
|
Arbutus Biopharma Corporation
Acuitas has No Further Rights to Use or Sublicense Arbutus LNP TechnologyArbutus Consolidates LNP Patent Estate Enabling RNAi, mRNA, and Gene-editing Therapeutics VANCOUVER, B.C. and WARMINSTER, Pa.,...
Arbutus Enters Exclusivity Agreement with Roivant Sciences
14 févr. 2018 20h50 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and WARMINSTER, Pa., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...
Arbutus Announces Departure of Chief Financial Officer; Appoints Interim CFO
13 févr. 2018 21h36 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and WARMINSTER, Pa., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...